SURVANTA (beractant) Survanta For the treatment and prevention
Health Care Professionals Parent Information Prescribing Information
 
Home
Download the 2007 NeoFax Manual.
Click Here

Watch the Survanta Dosing Video
Click Here

Download the National Respiratory Disease Newsletter
Click Here

Health Care ProfessionalsOver 800,000 infants treated since 1991*
Clinical Studies
Additional Studies
Follow-Up Studies
Prenatal Corticosteroids and Postnatal Surfactant
Epidemiologic Research
Surfactant Therapy Overview

Follow-Up Studies

Ferrara TB, Hoekstra RE, Couser RJ, et al: Survival and follow-up of infants born at 23 to 26 weeks of gestational age: Effects of surfactant therapy.
J Pediatr 1994;124:119-124.

Survanta Multidose Study Group: Two-year follow-up of infants treated for neonatal respiratory distress syndrome with bovine surfactant.
J Pediatr 1994;124:962-967.

Whitsett JA, Hull WM, Luse S: Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant.
Pediatrics 1991;87:505-510.

†The potential for allergic response to foreign protein still exists when using Survanta.

* IMS DDD Lung Surfactant Market Purchases July 1991 through June 2008. On file, Abbott Nutrition Marketing Research.